Table 3 of
Zyla, Mol Vis 2019; 25:446-461. Table 3 of
Zyla, Mol Vis 2019; 25:446-461.
Table 3. Treatment modalities for each patient included in the retrospective chart analysis.
| Tecfidera™ (n=51) | Control (n=53) | |||
|---|---|---|---|---|
| Females (n=39) | Males (n=12) | Females (n=40) | Males (n=13) | |
| Average # of drugs before Tecfidera™ | 1.92 ± 1.46 | 2.08 ± 1.78 | n/a^ | n/a |
| Average # of drugs | n/a | n/a | 1.78 ± 0.89 | 1.69 ± 0.75 |
| Number of patients taking each of the following drugs | ||||
| None or IVS* | 3 | 1 | 1 | 0 |
| Interferon β-1a | 24 | 7 | 12 | 5 |
| Interferon β-1b | 8 | 3 | 4 | 1 |
| Glatiramer acetate | 24 | 7 | 37 | 13 |
| Fingolimod | 6 | 2 | 6 | 1 |
| Teriflunomide | 0 | 0 | 5 | 0 |
| Mitoxantron | 1 | 1 | 0 | 0 |
| Natalizumab | 4 | 1 | 4 | 1 |
| Ocrelizumab | 0 | 0 | 1 | 1 |
| Alemtuzumab | 0 | 0 | 0 | 0 |
| Glatiramer acetate + IVS* | 4 | 0 | 0 | 0 |
| Cladribine | 1 | 0 | 0 | 0 |
| Interferon β-1b + IVS* | 1 | 1 | 0 | 0 |
| CCT + Interferon β-1b + IVS* | 1 | 1 | 0 | 0 |
| Interferon β-1a + IVS* | 0 | 1 | 0 | 0 |
| Intravenous Immunoglobulin | 0 | 1 | 0 | 0 |
| Laquinimab | 0 | 0 | 1 | 0 |